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in Asymptomatic Patients With Severe
Organic Mitral Regurgitation and
Preserved LV FunctionWe thank Dr. Jansen and colleagues for their com-
ments on our article (1). We agree that our results
clearly support the strategy of early surgery for
asymptomatic severe mitral regurgitation (MR), but
provide a better argument for the randomized clinical
trial to assess the best strategy for such patients
(2). Biases related to treatment selection and
referral are inherent in observational studies that
compare different treatment strategies. Although we
performed a propensity analysis to control for such
biases, this approach cannot completely remove the
effect of confounding. We also hope that randomized
clinical trials conﬁrm our results and prove the
efﬁcacy of early surgery for asymptomatic, severe MR.
Randomized clinical trials to determine the optimal
strategy for degenerativeMRhave never been properly
conducted because of ethical, logistical, and ﬁnancial
constraints (2). It is difﬁcult to enroll a large number of
such patients for adequate power and to obtain
informed consent from asymptomatic patients. All
of the participating centers should meet the
requirements for early preemptive surgery: expertise
in clinical evaluation and cardiac imaging to ensure
severe MR and the likelihood of a successful and
durable repair >95%, with a low operative mortality
<1% (3). Investigators of the Dutch AsymptomaticMitral Regurgitation trial (4) are to be commended for
initiating a difﬁcult randomized trial comparing early
surgery versus watchful waiting. However, we
are concerned about the possibility that their
randomized trial may not have sufﬁcient power
because randomized trials can include selected
patients who consent to participate. Observational
registries require randomized trials to explain their
results, but randomized trials also need unselected
registry data to examine generalizability, so the
two approaches are complementary (5). Hopefully
expecting that the results of a randomized trial will
be available in the near future, we suggest that our
data are useful in clinical practice for asymptomatic
patients with severe degenerative MR because
observational registry data are also important in
evaluating the effectiveness of early surgery.
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